A phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) in patients with glypican-3-positive (GPC3+) previously treated unresectable hepatocellular carcinoma.

225Ac-RYZ801 - BMS

https://www.asco.org/abstracts-presentations/255942

Brandon R. Mancini; Medhat Osman; Matthew Reilley; Lionel Aurelien Kankeu Fonkoua; Umair Majeed; Jeffrey Meyer; Jonathan McConathy; Amir Iravani; Samuel Mehr; Heying Duan; Hui Wang; Lucy Gong; James J. Harding

Dec 2, 2025